Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma
Seok‐Mo Kim(Gangnam Severance Hospital), Ki Cheong Park(Gangneung–Wonju National University)
Cited by 11
Related Papers
A new histone deacetylase inhibitor improves liver fibrosis in <scp>BDL</scp> rats through suppression of hepatic stellate cells
|British Journal of Pharmacology|2014|58
Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer
|Neoplasia|2017|20
Management of endocrine surgical disorders during COVID-19 pandemic: expert opinion for non-surgical options
|Updates in Surgery|2021|12
Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma
|International Journal of Molecular Sciences|2023|12
Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models
|International Journal of Molecular Sciences|2021|11